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The management of chronic pain, particularly neuropathic pain, still has significant unmet needs. In addition to 
inadequate symptomatic relief, there are concerns about adverse effects and addiction associated with treatments. 
The transplantation of cells that secrete neuroactive substances with analgesic properties into the central nervous 
system has only become of practical interest in more recent years, but provides a novel strategy to challenge current 
approaches in treating chronic pain. This review covers pre-clinical and clinical studies from both allogeneic and 
xenogeneic sources for management of chronic refractory pain. (Korean J Anesthesiol 2011; 60: 3-7)
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Introduction 
    Chronic pain of different etiologies affects brain structure 
and function [1]. It may cause other symptoms or conditions, 
including depression and anxiety, and may also contribute 
to decreased physical activity given the apprehension 
of exacerbating pain [2]. Despite recent advances in our 
understanding of chronic pain mechanisms and normal 
nociceptive transmission, the management of chronic pain, 
particularly neuropathic pain, is still far from resolved with 
currently available therapeutic regimens. Although many 
effective treatments are available, a number of adverse effects 
that interfere with the quality of life may be associated with 
treatment, and a significant number of patients obtain no 
relief from these treatments. Therefore, chronic pain is a major 
medical and societal problems resulting in enormous financial 
costs [3]. 
    Transplanting cells that secrete neuroactive substances with 
analgesic properties into the central nervous system (CNS) 
may have therapeutic potential for the long-term treatment 
of chronic pain [4-7]. Cell transplantation could provide 
analgesic effects similar to neuraxial drug delivery pumps such 
as the secretion of pain-reducing neuroactive substances at 
optimal sites and constant level, while overcoming problems 
of pump refilling and maintenance. In addition, these cell-
based approaches targeted to the CNS could alleviate most 
systemic side effects. Therefore, the selection of appropriate 
bioengineered cells as biological mini pumps can provide 
permanent management of chronic pain. This review focuses 
on the role of cell-based therapy in the management of chronic pain. 
The Mechanism of Cell Based Therapy for Pain 
    Cell transplants for pain are based on the concept of descending 
inhibitory modulation of sensory information. Descending 
inhibitory tracts from cell bodies in the periaqueductal 4 www.ekja.org
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gray, reticular formation, and nucleus magnus project to 
the dorsal horn. These inhibitory tracts contain a variety of 
neurotransmitters, including catecholamines and opioids, 
which play an important role in nociceptive responses [8,9]. 
Chromaffin cells [4-7], neural precursor cells [10], mesenchymal 
stem cells [11], and genetically engineered cells [12] can secrete 
neuroactive materials, including catecholamines, opioid 
peptides, and other neuropeptides with anti-nociceptive 
properties. Intrathecal transplantation of these cells induces 
analgesia in animal pain models.
Biomaterial Technology for Cell Implantation
    One of the biggest issues for organ transplantation is the 
shortage of donor tissues or organs. The low number of available 
grafts requires the use of xenogenic non-human donors, but 
the transplants undergo immunological rejection, limiting their 
survival. In addition, the continuous use of immunosuppressive 
agents to prevent immunological rejection often causes side 
effects, such as bacterial or viral infection and carcinogenesis. 
Analgesic effects correlate with graft viability and output 
[6,7,13], and xenogenic grafts are frequently rejected. 
Therefore, protecting grafts from immunological responses 
by encapsulating them within a semipermeable membrane 
using biocompatible materials allows for immunoisolation, 
which permits the inward diffusion of small molecule nutrients 
and oxygen, and outward diffusion of therapeutic material 
produced by implants, but preventing host immune system 
responses and improving long-term graft survival without 
immunosuppressants [5-7].
    One common design for microencapsulation involves 
enclosing cells within the lumen of a semipermeable membrane 
or flat sheet membrane of polyacrylonitrile/polyvinylchloride 
fiber [13]. For macroencapsulation, cells are usually suspended 
in a matrix within a hollow fiber membrane. The open ends of 
the hollow fiber are sealed, thereby forming a capsule within 
which the cells reside. The advantages of this technique include 
stability of the implant and ease of retrieval. However, the 
relatively thick fiber membrane is disadvantageous for cell 
viability and the efficient release of neuroactive materials, 
because there is a relatively large diffusion distance across the 
membrane. The loss of cell viability, in particular, severely limits 
the usefulness of macrocapsules [13]. This low grafting rate of 
cells transplanted and their consequent poor functions often 
cause low therapeutic efficacy of cell transplantation. Cells 
must have a suitable environment to overcome these problems. 
Microcapsules are much smaller, durable, and typically 
have a larger surface to volume ratio that is advantageous 
for the bi-directional diffusion of nutrients, oxygen, and 
bioactive materials, compared to macrocapsules. Therefore, 
microcapsules are more effective for the delivery of analgesic 
substances by transmembrane diffusion than macrocapsules 
[5-7]. In addition, the dimensions of microcapsules can be 
scaled easily to suit different species and implantation sites, 
although they are fragile and cannot be retrieved easily.
Application of Cell-based Therapies for Pain
Chromaffin cells 
    Chromaffin cells produce and release catecholamines, opioid 
peptides of various sizes, and other neuropeptides that produce 
analgesia in the spinal space [5-7,14]. Cerebrospinal fluid (CSF) 
in a neuropathic pain model induced by loose ligation of the 
sciatic nerve induces catecholamines release from chromaffin 
cells [15]. Long-term survival of intrathecally implanted 
encapsulated bovine chromaffin cells reduced mechanical 
and cold allodynia in a rat model of neuropathic pain [5-7]. 
In addition, norepinephrine and met-enkephalin levels of   
CSF were higher in the rats that received microencapsulated 
chromaffin cells [6]. However, due to concerns over the risk 
of prion transmission, the use of bovine adrenal medulla 
may be precluded in future clinical trials. Intrathecal porcine 
chromaffin cells also suppress nociceptive behavior in animal 
pain models [16,17].
Neural precursor cells
    Chromaffin cells stem from the neural crest, which plays 
a paradigmatic role in the mechanism that determines 
cell fate in the nervous system. Two types of fetal human 
chromaffin cells with an adrenergic phenotype between 7 and 
10 gestational weeks could be obtained in vitro [18] through 
specific procedures, but these cells could be exploited for pain 
therapy [19]. Allodynia after injury may involve the pathological 
loss of inhibition in the spinal cord [20]. Following spinal 
cord or peripheral nerve injury, there is an apparent loss of 
γ-aminobutyric acid (GABA) ergic inhibitory interneurons 
in the spinal cord [21]. Bioreactor-expanded human neural 
precursor cells differentiated to a GABAergic phenotype prior to 
transplantation decreased allodynia in rat model of neuropathic 
pain induced by ligation of the spinal nerve [10].
Stem cells 
    Stem cells hold great potential for the regeneration of 
damaged tissues [22]. They limit neuronal damage in a 
wide variety of experimental neurologic injuries, including 
Parkinson’s disease [23], spinal cord injury [24], and peripheral 
nerve damage [25]. Intra-brain microinjection of human 5 www.ekja.org
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mesenchymal stem cells (hMSC) reduced the mRNA levels 
of the proinflammatory interleukin-1beta gene, as well as 
astrocytic and microglial cell activation in neuropathic mice 
[26]. In vitro, genetically engineered hMSCs transfected with the 
human preproenkephalin (hPPE) gene increased production 
of the opioid peptide, met-enkephalin [11]. In addition, hybrid 
cell fusions of chromaffin cells and hMSCs expressed some 
characteristics of the chromaffin cell phenotype, suggesting 
that novel cellular production could be developed by a 
"reprogramming" mechanism through the application of 
targeted cell fusion strategies [27]. Stem cells can provide a 
sufficient number of chromaffin cells due to the paucity of 
human adrenal tissue.
Cell lines
    Immortalized cell lines are an alternative to chromaffin 
cells for cellular implantation, offering the advantage of shelf 
availability as well as a more detailed characterization of their 
phenotype and histocompatibility. The most useful cell lines 
are derived from chromaffin cells, with ongoing creation of 
human chromaffin cell lines that may be useful in treating 
traumatic and neurodegenerative disease [28-31]. Initially, 
the archetypal adrenal medullary cell lines were derived from 
spontaneous pheochromocytoma of the medulla, either from 
murine or human sources, such as the rat PC12 cell line and the 
human KNA and KAT45 cell lines [28-30]. Modern techniques 
use tumorigenesis and targeted oncogenesis in vivo, where 
isolation of specific populations of mouse endocrine cells 
allows exploration of the regulatory pathways in the chromaffin 
phenotype [31]. In addition, conditional immortalization with 
retroviral infection of chromaffin precursors has provided 
homogeneous and expandable chromaffin cells for transplant 
studies in animal models of pain [32]. This same strategy of 
immortalization with conditionally expressed oncogenes 
has been expanded to create the first disimmortalizable 
chromaffin cells, with an excisable oncogenic cassette, as might 
be envisioned for the creation of human chromaffin cell lines 
[33,34].
    The use of monoamine-secreting cell lines for the continuous 
delivery of catecholamines and/or serotonin to the spinal cord 
may be an alternative strategy for the treatment of chronic 
pain. An encapsulated neuroblastoma cell line NB69 given 
intrathecally produced analgesia to neuropathic pain in rats 
by producing monoamines (dopamine and serotonin) [35]. 
Immortalized chromaffin cells of rats were genetically modified 
to improve opioid peptide expression through lipid-mediated 
gene transfer. When implanted into the spinal space, they 
reduced evoked c-fos protein expression in rat dorsal horn 
neurons in the formalin tonic pain model [36]. The use of such 
expandable cell lines for chronic spinal delivery of opiates could 
offer an attractive and safe alternative strategy based on ex vivo 
gene therapy for the control of opioid-sensitive chronic pain.
Macrophages
    An ex vivo gene transfer of the human proenkephalin gene to 
autologous macrophages of rats was performed with a non-viral 
vector. Intrathecal implantation of these cells alleviated heat 
hyperalgesia and allodynia induced by sciatic nerve constriction 
for four weeks. The transplanted macrophages migrated into 
the spinal cord and expressed proenkephalin mRNA and met-
enkephalin protein [37]. 
Clinical trial 
    Clinical trials with allografts consisting of whole-tissue 
fragments implanted into the subarachnoid space of the 
lumbar spinal cord showed that the allogeneic grafts could 
control cancer pain in two patients over 1 year based on 
patient reported pain scores, morphine intake, and CSF 
levels of met-enkephalin [38]. A Phase II open study in 
France showed the feasibility and the safety of chromaffin 
cell allografts administered intrathecally to cancer patients 
to relieve intractable pain [39]. The CNS is considered an 
immune privileged site. Non-human leukocyte antigen (HLA)-
matched and unencapsulated tissue was grafted and analgesic 
efficacy was indicated by the reduction or stabilization in 
complementary opioid intake, although lymphocyte counts 
increased in CSF. Further work on the purification and/or the 
immunoisolation of tissues grafted in the CNS will be necessary, 
particularly for long-term or repeated grafting.
Conclusions
    Cell based treatment offers certain benefits in controlled, 
safe, long-term delivery of analgesic molecules in experimental 
cell-based therapies. In addition, novel technologies such 
as encapsulation and engineered cell lines hold promise for 
future applications. Initial clinical trials have been generally 
encouraging, although evidence for translation into clinical 
use in humans is limited. Together, these studies suggest that 
cell transplantation is a potentially valuable complementary 
approach in the therapeutic management of chronic pain.
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